That’s what the Bayer ceo told a German newspaper over the weekend. Werner Wenning acknowleged to Tagesspiegel that “you can’t rule out anything, especially not in the current environment.” At the same time, he maintained Bayer’s high market value should protect the drugmaker from a takeover.

“Five years ago, our market value was 14 billion euros ($20 billion). Now, now it is 42 billion euros,” he told the paper, according to Reuters. “I don’t think that looks bad.”

Bayer will get better than expected synergies from its purchase of Schering, Wenning insisted, and he did not rule out further takeovers to bolster the health business, pointing to a fragmented pharma market and the looming expiration of many patents, according to Reuters.

Last week, you may recall, there was speculation Pfizer was interested in making a bid, despite continued assertions from Pfizer management that big deals are not in the offing (a point that is not entirely shared by everyone on the Pfizer board, so we are told).